期刊
SCIENTIFIC REPORTS
卷 6, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/srep28910
关键词
-
资金
- NIH/NCI [RO1CA120895]
Although circulating tumor cells (CTCs) have potential as diagnostic biomarkers for cancer, determining their prognostic role in cancer patients undergoing treatment is a challenge. We evaluated the prognostic value of programmed death-ligand 1 (PD(L1) expression in CTCs in colorectal and prostate cancer patients undergoing treatment. Peripheral blood samples were collected from 62 metastatic colorectal cancer patients and 30 metastatic prostate cancer patients. CTCs were isolated from the samples using magnetic separation with the cell(surface vimentin(CSV)(specific 84(1 monoclonal antibody that detects epithelial(mesenchymal transitioned (EMT) CTCs. CTCs were enumerated and analyzed for PD(L1 expression using confocal microscopy. PD(L1 expression was detectable in CTCs and was localized in the membrane and/or cytoplasm and nucleus. CTC detection alone was not associated with poor progression(free or overall survival in colorectal cancer or prostate cancer patients, but nuclear PD(L1 (nPD(L1) expression in these patients was significantly associated with short survival durations. These results demonstrated that nPD(L1 has potential as a clinically relevant prognostic biomarker for colorectal and prostate cancer. Our data thus suggested that use of CTC(based models of cancer for risk assessment can improve the standard cancer staging criteria and supported the incorporation of nPD(L1 expression detection in CTCs detection in such models.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据